Veracyte, Inc. $VCYT Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC grew its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT) by 409.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 19,947 shares of the biotechnology company’s stock after purchasing an additional 16,032 shares during the period. SG Americas Securities LLC’s holdings in Veracyte were worth $539,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Police & Firemen s Retirement System of New Jersey raised its stake in Veracyte by 4.6% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 17,991 shares of the biotechnology company’s stock worth $486,000 after acquiring an additional 790 shares during the period. PNC Financial Services Group Inc. grew its holdings in shares of Veracyte by 4.0% during the second quarter. PNC Financial Services Group Inc. now owns 22,732 shares of the biotechnology company’s stock valued at $614,000 after purchasing an additional 865 shares during the last quarter. Campbell & CO Investment Adviser LLC raised its position in shares of Veracyte by 127.4% during the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 173,638 shares of the biotechnology company’s stock worth $4,693,000 after purchasing an additional 97,296 shares during the period. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Veracyte by 19.2% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 279,188 shares of the biotechnology company’s stock worth $7,546,000 after purchasing an additional 44,992 shares during the last quarter. Finally, Los Angeles Capital Management LLC boosted its position in Veracyte by 62.4% during the 2nd quarter. Los Angeles Capital Management LLC now owns 30,013 shares of the biotechnology company’s stock valued at $811,000 after purchasing an additional 11,531 shares during the period.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Needham & Company LLC increased their target price on Veracyte from $41.00 to $44.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. Guggenheim increased their price objective on shares of Veracyte from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Canaccord Genuity Group boosted their target price on shares of Veracyte from $40.00 to $43.00 and gave the company a “hold” rating in a research note on Wednesday, November 5th. Wall Street Zen upgraded shares of Veracyte from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 16th. Finally, Zacks Research raised Veracyte from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $43.38.

Veracyte Price Performance

VCYT opened at $47.71 on Thursday. The business has a 50 day moving average price of $37.47 and a two-hundred day moving average price of $31.14. The company has a market capitalization of $3.77 billion, a price-to-earnings ratio of 144.58 and a beta of 2.16. Veracyte, Inc. has a 1-year low of $22.61 and a 1-year high of $50.71.

Veracyte (NASDAQ:VCYT) last announced its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.19. The business had revenue of $131.87 million during the quarter, compared to analyst estimates of $124.62 million. Veracyte had a return on equity of 6.07% and a net margin of 5.50%.The company’s revenue was up 13.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.33 earnings per share. Veracyte has set its FY 2025 guidance at EPS. Equities analysts expect that Veracyte, Inc. will post 0.68 EPS for the current fiscal year.

Insider Buying and Selling

In other Veracyte news, Director Jens Holstein sold 10,000 shares of the company’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $42.36, for a total value of $423,600.00. Following the transaction, the director owned 27,199 shares of the company’s stock, valued at approximately $1,152,149.64. This represents a 26.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Karin Eastham sold 9,674 shares of the stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $40.02, for a total value of $387,153.48. Following the sale, the director owned 13,554 shares of the company’s stock, valued at $542,431.08. This trade represents a 41.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 98,549 shares of company stock worth $4,109,580. 1.40% of the stock is owned by insiders.

Veracyte Company Profile

Veracyte, Inc engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H.